In Dec, 2019 TIRmed Pharma was awarded funding from the European Union´s Horizon 2020 research and innovation progamme under grant agreement number 885787-TIR-C regarding the development of a cream to treat immune responses in atopic dermatitis.
- TIRmed Pharma raises 5.4 MSEK in equity to continue pursuing preclinical development of new antiviral treatment and a topical treatment for atopic eczema.
- New publication
- TIRmed Pharma receives approval to grant patents in Europe
- TIRmed Pharma receives approval of patent in the US
- TIRmed Pharma receives SME Instrument Phase 1 grant from EU Grant No 885787-TIR-C